retatrutide clinical trials phase 3 New GLP-3 drug significantly slashes both weight and blood sugar levels in III trial retatrutide weight loss clinical data

Recently, a phase 2b study for people with obesity has been completed and a press release revealed that danuglipron doses between 40 and 200 mg twice daily led up to 11.7% WL compared to 1.4% weight gain with placebo after 32 weeks of treatment [27]

Smith DB, Johnson KS: Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase

Auerbach, P

Safety, side effects, and clinical oversight The FDA-labeled side-effect profile for GLP-1 receptor agonists and the GIP/GLP-1 dual agonist tirzepatide is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common

Management of hyperpigmentation in darker racial ethnic groups